Advertisement

Person › Details
John V. Oyler (BeiGene Ltd. (Nasdaq: BGNE, HKEX: 06160, SSE: 688235))
Oyler, John V. (BeiGene 201305 CEO + Co-Founder)
Record changed: 2023-09-28 |
Advertisement

More documents for John V. Oyler
- [1] BeiGene, Ltd.. (12/23/24). "Press Release: BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference". San Mateo, CA....
- [2] BeiGene, Ltd.. (9/19/23). "Press Release: BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody Tevimbra (tislelizumab)". Basel & Beijing & Cambridge, MA....
- [3] BeiGene, Ltd.. (7/13/22). "Press Release: BeiGene Appoints Chan Lee as General Counsel". Cambridge, MA, Basel & Beijing....
- [4] BeiGene, Ltd.. (5/17/22). "Press Release: BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland". Cambridge, MA, Basel & Beijing....
- [5] BeiGene, Ltd.. (11/23/21). "Press Release: BeiGene Closes on Property for New U.S. Manufacturing and Clinical R&D Center". Hopewell, NJ, Cambridge, MA & Beijing....
- [6] BeiGene, Ltd.. (10/31/19). "Press Release: BeiGene Announces Global Strategic Oncology Collaboration with Amgen". Cambridge, MA & Beijing....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top